IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases

Monica Rodolfo, Cecilia Melani, Chiara Zilocchi, Barbara Cappetti, Elena Luison, Ivano Arioli, Mariella Parenza, Silvana Canevari, Mario P. Colombo

Research output: Contribution to journalArticle

Abstract

We evaluated whether antibody response correlates with tumor therapy by cytokine gene-modified tumor cell vaccines. To characterize the antibody (Ab) response against a known antigen, colon carcinoma C26 cells and C26 variants engineered to produce interleukin (IL) 12 or IL-4 were further transduced to express the human tumor-associated antigen gp38 folate receptor (FR) α. Irradiated IL-12- and IL-4-producing C26/FRα cell vaccines cured 50 and 30% of mice bearing C26/FRα lung micrometastases. Treatment induced a rapid, CD4-dependent Ab production dominated by IgG2a and IgG1 in response to the IL-12 or IL-4 vaccine, respectively. In contrast, untreated tumor-bearing mice showed a late serological response dominated by IgM. Anti-FRα IgG1 and IgG2a were able to suppress tumor metastases upon passive transfer in vivo. Sera from mice cured by the IL-12 vaccine displayed a higher binding activity, a higher anti-FRα IgG2a content, and a higher complement-mediated tumor cell lysis in vitro compared to the sera from nonresponder mice. Such a correlation was not found in the sera of mice treated with the IL-4 vaccine. These data indicate that cytokine-producing tumor cell vaccines strongly influence antibody response, and that in the case of the IL-12-based vaccine, the Ab titer correlates with the therapeutic response, thus suggesting its use for monitoring the outcome of vaccination in cancer patients.

Original languageEnglish
Pages (from-to)5812-5817
Number of pages6
JournalCancer Research
Volume58
Issue number24
Publication statusPublished - Dec 15 1998

Fingerprint

Cancer Vaccines
Interleukin-12
Folic Acid
Interleukin-4
Vaccines
Immunoglobulin G
Antibody Formation
Neoplasm Metastasis
Neoplasms
Serum
Cytokines
Neoplasm Micrometastasis
Neoplasm Antigens
Genetic Therapy
Colon
Vaccination
Carcinoma
Antigens
Lung
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases. / Rodolfo, Monica; Melani, Cecilia; Zilocchi, Chiara; Cappetti, Barbara; Luison, Elena; Arioli, Ivano; Parenza, Mariella; Canevari, Silvana; Colombo, Mario P.

In: Cancer Research, Vol. 58, No. 24, 15.12.1998, p. 5812-5817.

Research output: Contribution to journalArticle

Rodolfo, Monica ; Melani, Cecilia ; Zilocchi, Chiara ; Cappetti, Barbara ; Luison, Elena ; Arioli, Ivano ; Parenza, Mariella ; Canevari, Silvana ; Colombo, Mario P. / IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases. In: Cancer Research. 1998 ; Vol. 58, No. 24. pp. 5812-5817.
@article{015284a4c15b4b54858f63c8a864f7c4,
title = "IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases",
abstract = "We evaluated whether antibody response correlates with tumor therapy by cytokine gene-modified tumor cell vaccines. To characterize the antibody (Ab) response against a known antigen, colon carcinoma C26 cells and C26 variants engineered to produce interleukin (IL) 12 or IL-4 were further transduced to express the human tumor-associated antigen gp38 folate receptor (FR) α. Irradiated IL-12- and IL-4-producing C26/FRα cell vaccines cured 50 and 30{\%} of mice bearing C26/FRα lung micrometastases. Treatment induced a rapid, CD4-dependent Ab production dominated by IgG2a and IgG1 in response to the IL-12 or IL-4 vaccine, respectively. In contrast, untreated tumor-bearing mice showed a late serological response dominated by IgM. Anti-FRα IgG1 and IgG2a were able to suppress tumor metastases upon passive transfer in vivo. Sera from mice cured by the IL-12 vaccine displayed a higher binding activity, a higher anti-FRα IgG2a content, and a higher complement-mediated tumor cell lysis in vitro compared to the sera from nonresponder mice. Such a correlation was not found in the sera of mice treated with the IL-4 vaccine. These data indicate that cytokine-producing tumor cell vaccines strongly influence antibody response, and that in the case of the IL-12-based vaccine, the Ab titer correlates with the therapeutic response, thus suggesting its use for monitoring the outcome of vaccination in cancer patients.",
author = "Monica Rodolfo and Cecilia Melani and Chiara Zilocchi and Barbara Cappetti and Elena Luison and Ivano Arioli and Mariella Parenza and Silvana Canevari and Colombo, {Mario P.}",
year = "1998",
month = "12",
day = "15",
language = "English",
volume = "58",
pages = "5812--5817",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases

AU - Rodolfo, Monica

AU - Melani, Cecilia

AU - Zilocchi, Chiara

AU - Cappetti, Barbara

AU - Luison, Elena

AU - Arioli, Ivano

AU - Parenza, Mariella

AU - Canevari, Silvana

AU - Colombo, Mario P.

PY - 1998/12/15

Y1 - 1998/12/15

N2 - We evaluated whether antibody response correlates with tumor therapy by cytokine gene-modified tumor cell vaccines. To characterize the antibody (Ab) response against a known antigen, colon carcinoma C26 cells and C26 variants engineered to produce interleukin (IL) 12 or IL-4 were further transduced to express the human tumor-associated antigen gp38 folate receptor (FR) α. Irradiated IL-12- and IL-4-producing C26/FRα cell vaccines cured 50 and 30% of mice bearing C26/FRα lung micrometastases. Treatment induced a rapid, CD4-dependent Ab production dominated by IgG2a and IgG1 in response to the IL-12 or IL-4 vaccine, respectively. In contrast, untreated tumor-bearing mice showed a late serological response dominated by IgM. Anti-FRα IgG1 and IgG2a were able to suppress tumor metastases upon passive transfer in vivo. Sera from mice cured by the IL-12 vaccine displayed a higher binding activity, a higher anti-FRα IgG2a content, and a higher complement-mediated tumor cell lysis in vitro compared to the sera from nonresponder mice. Such a correlation was not found in the sera of mice treated with the IL-4 vaccine. These data indicate that cytokine-producing tumor cell vaccines strongly influence antibody response, and that in the case of the IL-12-based vaccine, the Ab titer correlates with the therapeutic response, thus suggesting its use for monitoring the outcome of vaccination in cancer patients.

AB - We evaluated whether antibody response correlates with tumor therapy by cytokine gene-modified tumor cell vaccines. To characterize the antibody (Ab) response against a known antigen, colon carcinoma C26 cells and C26 variants engineered to produce interleukin (IL) 12 or IL-4 were further transduced to express the human tumor-associated antigen gp38 folate receptor (FR) α. Irradiated IL-12- and IL-4-producing C26/FRα cell vaccines cured 50 and 30% of mice bearing C26/FRα lung micrometastases. Treatment induced a rapid, CD4-dependent Ab production dominated by IgG2a and IgG1 in response to the IL-12 or IL-4 vaccine, respectively. In contrast, untreated tumor-bearing mice showed a late serological response dominated by IgM. Anti-FRα IgG1 and IgG2a were able to suppress tumor metastases upon passive transfer in vivo. Sera from mice cured by the IL-12 vaccine displayed a higher binding activity, a higher anti-FRα IgG2a content, and a higher complement-mediated tumor cell lysis in vitro compared to the sera from nonresponder mice. Such a correlation was not found in the sera of mice treated with the IL-4 vaccine. These data indicate that cytokine-producing tumor cell vaccines strongly influence antibody response, and that in the case of the IL-12-based vaccine, the Ab titer correlates with the therapeutic response, thus suggesting its use for monitoring the outcome of vaccination in cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0032535410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032535410&partnerID=8YFLogxK

M3 - Article

C2 - 9865740

AN - SCOPUS:0032535410

VL - 58

SP - 5812

EP - 5817

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 24

ER -